Meta-analysis on Vitamin D receptor and cancer risk: Focus on the role of TaqI, ApaI, and Cdx2 polymorphisms

European Journal of Cancer Prevention

Volumn 25, Issue 1, 2016, Pages 85-96

  Serrano, Davide ^a   Gnagnarella, Patrizia ^a   Raimondi, Sara ^a   Gandini, Sara ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

ApaI; Cancer; Cdx2; Polymorphisms; TaqI; Vitamin D; Vitamin D receptor

Indexed keywords

PROTEIN APAI; PROTEIN DERIVATIVE; PROTEIN TAQI; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; CDX2 PROTEIN, HUMAN; GGGCCC-SPECIFIC TYPE II DEOXYRIBONUCLEASES; HOMEODOMAIN PROTEIN; TCGA-SPECIFIC TYPE II DEOXYRIBONUCLEASES; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE; VDR PROTEIN, HUMAN;

ARTICLE; CANCER RISK; COLORECTAL CANCER; GENE CLUSTER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; NEOPLASM; RISK FACTOR;

CASE-CONTROL STUDIES; CDX2 TRANSCRIPTION FACTOR; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; GENETIC PREDISPOSITION TO DISEASE; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL; RISK FACTORS;

EID: 84948698515     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000132     Document Type: Article

References (114)

1. Abbas S, Nieters A, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, et al. (2008). Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. Breast Cancer Res 10:R31.
2. Anderson LN, Cotterchio M, Cole DE, Knight JA (2011). Vitamin D-related geneticvariants, interactions with Vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev 20:1708-1717.
3. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR (2006). Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 57:234-240.
4. Andersson P, Varenhorst E, Soderkvist P (2006). Androgen receptor and Vitamin D receptor gene polymorphisms and prostate cancer risk. Eur J Cancer 42:2833-2837.
5. Anic GM, Thompson RC, Nabors LB, Olson JJ, Browning JE, Madden MH, et al. (2012). An exploratory analysis of common genetic variants in the Vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. Cancer Causes Control 23:1443-1449.
6. Arai H, Miyamoto KI, Yoshida M, Yamamoto H, Taketani Y, Morita K, et al. (2001). The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human Vitamin D receptor gene. J Bone Miner Res 16:1256-1264.
7. Autier P, Gandini S (2007). Vitamin D supplementation and total mortality: a metaanalysis of randomized controlled trials. Arch Intern Med 167:1730-1737.
8. Bai Y, Yu Y, Yu B, Ge J, Ji J, Lu H, et al. (2009). Association of Vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Med Genet 10:125.
9. Bai YH, Lu H, Hong D, Lin CC, Yu Z, Chen BC (2012). Vitamin D receptor genepolymorphisms and colorectal cancer risk: a systematic meta-analysis. World J Gastroenterol 18:1672-1679.
10. Barroso E, Fernandez LP, Milne RL, Pita G, Sendagorta E, Floristan U, et al. (2008). Genetic analysis of the Vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies. BMC Cancer 8:385.
11. Bektas-Kayhan K, Unur M, Yaylim-Eraltan I, Ergen HA, Toptas B, Hafiz G, et al. (2010). Association of Vitamin D receptor Taq I polymorphism and susceptibility to oral squamous cell carcinoma. In Vivo 24:755-759.
12. Bentley RW, Keown DA, Gearry RB, Cameron VA, Keenan J, Roberts RL, Day AS (2012). Vitamin D receptor polymorphisms in colorectal cancer in New Zealand: an association study. N Z Med J 125:47-51.
13. Blazer DG III, Umbach DM, Bostick RM, Taylor JA (2000). Vitamin D receptor polymorphisms and prostate cancer. Mol Carcinog 27:18-23.
14. Buyru N, Tezol A, Yosunkaya-Fenerci E, Dalay N (2003). Vitamin D receptor gene polymorphisms in breast cancer. Exp Mol Med 35:550-555.
15. Chaimuangraj S, Thammachoti R, Ongphiphadhanakul B, Thammavit W (2006). Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls. Asian Pac J Cancer Prev 7:136-139.
16. Chakraborty A, Mishra AK, Soni A, Regina T, Mohil R, Bhatnagar D, et al. (2009). Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians. Cancer Detect Prev 32:386-394.
17. Chang CK, Mulholland HG, Cantwell MM, Anderson LA, Johnston BT, McKnight AJ, et al. (2012). Vitamin D receptor gene variants and esophageal adenocarcinoma risk: a population-based case-control study. J Gastrointest Cancer 43:512-517.
18. Cicek MS, Liu X, Schumacher FR, Casey G, Witte JS (2006). Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 15:2549-2552.
19. Clendenen TV, Arslan AA, Koenig KL, Enquist K, Wirgin I, Agren A, et al. (2008). Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett 260:209-215.
20. Correa-Cerro L, Berthon P, Haussler J, Bochum S, Drelon E, Mangin P, et al. (1999). Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet 105:281-287.
21. Crofts LA, Hancock MS, Morrison NA, Eisman JA (1998). Multiple promoters direct the tissue-specific expression of novel N-terminal variant human Vitamin D receptor gene transcripts. Proc Natl Acad Sci USA 95:10529-10534.
22. Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR (1999). Association of A Vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer 83:723-726.
23. Dalessandri KM, Miike R, Wiencke JK, Farren G, Pugh TW, Manjeshwar S, et al. (2012). Vitamin D receptor polymorphisms and breast cancer risk in a highincidence population: a pilot study. J Am Coll Surg 215:652-657.
24. Deeb KK, Trump DL, Johnson CS (2007). Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7:684-700.
25. Dunning AM, McBride S, Gregory J, Durocher F, Foster NA, Healey CS, et al. (1999). No association between androgen or Vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis 20:2131-2135.
26. Durrin LK, Haile RW, Ingles SA, Coetzee GA (1999). Vitamin D receptor 3?-untranslated region polymorphisms: lack of effect on mRNA stability. Biochim Biophys Acta 1453:311-320.
27. Engel LS, Orlow I, Sima CS, Satagopan J, Mujumdar U, Roy P, et al. (2012). Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 21:1856-1867.
28. Falleti E, Bitetto D, Fabris C, Cussigh A, Fontanini E, Fornasiere E, et al. (2010). Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol 16:3016-3024.
29. Flugge J, Krusekopf S, Goldammer M, Osswald E, Terhalle W, Malzahn U, et al. (2007). Vitamin D receptor haplotypes protect against development of colorectal cancer. Eur J Clin Pharmacol 63:997-1005.
30. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J (2003). Analysis of the Vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res 164:239-246.
31. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. (2011). Metaanalysis of observational studies of serum 25-hydroxyVitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128:1414-1424.
32. Gapska P, Scott RJ, Serrano-Fernandez P, Mirecka A, Rassoud I, Gorski B, et al. (2009). Vitamin D receptor variants and the malignant melanoma risk: a population-based study. Cancer Epidemiol 33:103-107.
33. Gnagnarella P, Pasquali E, Serrano D, Raimondi S, Disalvatore D, Gandini S (2014). Vitamin D receptor polymorphism FokI and cancer risk: a comprehensive meta-analysis. Carcinogenesis 35:1913-1919.
34. Grant DJ, Hoyo C, Akushevich L, Iversen ES, Whitaker R, Marks J, et al. (2013). Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. Gynecol Oncol 129:173-178.
35. Greenland S (1987). Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1-30.
36. Gu H, Wang X, Zheng L, Tang W, Dong C, Wang L, et al. (2014). Vitamin D receptor gene polymorphisms and esophageal cancer risk in a Chinese population: a negative study. Med Oncol 31:827.
37. Gunduz M, Cacina C, Toptas B, Yaylim-Eraltan I, Tekand Y, Isbir T (2012). Association of Vitamin D receptor gene polymorphisms with colon cancer. Genet Test Mol Biomarkers 16:1058-1061.
38. Guo YJ, Shi ZM, Liu JD, Lei N, Chen QH, Tang Y (2012). Meta-analysis of the relation between the VDR gene TaqI polymorphism and genetic susceptibility to prostate cancer in Asian populations. Asian Pac J Cancer Prev 13:4441-4444.
39. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, et al. (2000). Association of Vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 60:305-308.
40. Han J, Colditz GA, Hunter DJ (2007). Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis 28:390-397.
41. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558.
42. Hiraki LT, Qu C, Hutter CM, Baron J, Berndt SI, Bezieau S, et al. (2013). Genetic predictors of circulating 25-hydroxyVitamin D and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 22:2037-2046.
43. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U (2007). Comprehensive association analysis of the Vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 16:1990-1999.
44. Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL (2009). Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 18:1929-1933.
45. Hou MF, Tien YC, Lin GT, Chen CJ, Liu CS, Lin SY, et al. (2002). Association of Vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res Treat 74:1-7.
46. Huang J, Huang J, Ma Y, Wang H, Yang J, Xiong T, et al. (2013). The Cdx-2 polymorphism in the VDR gene is associated with increased risk of cancer: a meta-analysis. Mol Biol Rep 40:4219-4225.
47. Huang SP, Chou YH, Wayne Chang WS, Wu MT, Chen YY, Yu CC, et al. (2004). Association between Vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett 207:69-77.
48. Hughes DJ, Hlavata I, Soucek P, Pardini B, Naccarati A, Vodickova L, et al. (2011). Variation in the Vitamin D receptor gene is not associated with risk of colorectal cancer in the Czech Republic. J Gastrointest Cancer 42:149-154.
49. Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, et al. (2000). Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 6:498-504.
50. John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA (2005). Sun exposure, Vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 65:5470-5479.
51. Karami S, Brennan P, Hung RJ, Boffetta P, Toro J, Wilson RT, et al. (2008). Vitamin D receptor polymorphisms and renal cancer risk in Central and Eastern Europe. J Toxicol Environ Health A 71:367-372.
52. Kizildag S, Gulsu E, Bagci O, Yuksel E, Canda T (2011). Vitamin D receptor gene polymorphisms and male breast cancer risk in Turkish population. J BUON 16:640-645.
53. Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Reichrath J (2009). The relevance of Vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 29:3511-3536.
54. Kostner K, Denzer N, Koreng M, Reichrath S, Graber S, Klein R, et al. (2012). Association of genetic variants of the Vitamin D receptor (VDR) with cutaneous squamous cell carcinomas (SCC) and basal cell carcinomas (BCC): a pilot study in a German population. Anticancer Res 32:327-333.
55. Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, et al. (2013). Genetic analyses reveal a role for Vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS One 8:e64053.
56. Lauridsen AL, Vestergaard P, Hermann AP, Brot C, Heickendorff L, Mosekilde L, et al. (2005). Plasma concentrations of 25-hydroxy-Vitamin D and 1, 25-dihydroxy-Vitamin D are related to the phenotype of Gc (Vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 77:15-22.
57. Lesiak A, Norval M, Wodz-Naskiewicz K, Pawliczak R, Rogowski-Tylman M, Sysa-Jedrzejowska A, et al. (2011). An enhanced risk of basal cell carcinoma is associated with particular polymorphisms in the VDR and MTHFR genes. Exp Dermatol 20:800-804.
58. Li C, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, et al. (2008). Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer 122:2077-2084.
59. Liu N, Nguyen L, Chun RF, Lagishetty V, Ren S, Wu S, et al. (2008). Altered endocrine and autocrine metabolism of Vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology 149:4799-4808.
60. Liu Y, Li C, Chen P, Li X, Li M, Guo H, et al. (2013). Polymorphisms in the Vitamin D receptor (VDR) and the risk of ovarian cancer: a meta-analysis. PLoS One 8:e66716.
61. Liu Z, Calderon JI, Zhang Z, Sturgis EM, Spitz MR, Wei Q (2005). Polymorphisms of Vitamin D receptor gene protect against the risk of head and neck cancer. Pharmacogenet Genomics 15:159-165.
62. Luo S, Guo L, Li Y, Wang S (2014). Vitamin D receptor gene ApaI polymorphism and breast cancer susceptibility: a meta-analysis. Tumour Biol 35:785-790.
63. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, et al. (2007). Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 16:2566-2571.
64. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, et al. (1998). Vitamin D receptor polymorphisms, circulating Vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 7:385-390.
65. Macaskill P, Walter SD, Irwig L (2001). A comparison of methods to detect publication bias in meta-analysis. Stat Med 20:641-654.
66. Mahmoudi T, Mohebbi SR, Pourhoseingholi MA, Fatemi SR, Zali MR (2010). Vitamin D receptor gene ApaI polymorphism is associated with susceptibility to colorectal cancer. Dig Dis Sci 55:2008-2013.
67. Maistro S, Snitcovsky I, Sarkis AS, da Silva IA, Brentani MM (2004). Vitamin D receptor polymorphisms and prostate cancer risk in Brazilian men. Int J Biol Markers 19:245-249.
68. McCullough ML, Stevens VL, Diver WR, Feigelson HS, Rodriguez C, Bostick RM, et al. (2007). Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res 9:R9.
69. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, et al. (2002). The role of Vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Hum Genet 47:413-418.
70. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E (2007). Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyVitamin D and 1, 25-dihydroxyVitamin D, and prostate cancer risk. Prostate 67:911-923.
71. Minambres I, Sanchez-Hernandez J, Sanchez-Quesada JL, Rodriguez J, de Leiva A, Perez A (2012). The association of hypovitaminosis D with the metabolic syndrome is independent of the degree of obesity. ISRN Endocrinol 2012691803.
72. Mishra DK, Wu Y, Sarkissyan M, Sarkissyan S, Chen Z, Shang X, et al. (2013). Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One 8:e57967.
73. Mittal RD, Manchanda PK, Bhat S, Bid HK (2007). Association of vitamin-D receptor (Fok-I) gene polymorphism with bladder cancer in an Indian population. BJU Int 99:933-937.
74. Muindi JR, Adjei AA, Wu ZR, Olson I, Huang H, Groman A, et al. (2013). Serum Vitamin D metabolites in colorectal cancer patients receiving cholecalciferol supplementation: correlation with polymorphisms in the Vitamin D genes. Horm Cancer 4:242-250.
75. Oakley-Girvan I, Feldman D, Eccleshall TR, Gallagher RP, Wu AH, Kolonel LN, et al. (2004). Risk of early-onset prostate cancer in relation to germ line polymorphisms of the Vitamin D receptor. Cancer Epidemiol Biomarkers Prev 13:1325-1330.
76. Obara W, Suzuki Y, Kato K, Tanji S, Konda R, Fujioka T (2007). Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population. Int J Urol 14:483-487.
77. Ochs-Balcom HM, Cicek MS, Thompson CL, Tucker TC, Elston RC, Plummer J, et al. (2008). Association of Vitamin D receptor gene variants, adiposity and colon cancer. Carcinogenesis 29:1788-1793.
78. Onen IH, Ekmekci A, Eroglu M, Konac E, Yesil S, Biri H (2008). Association of genetic polymorphisms in Vitamin D receptor gene and susceptibility to sporadic prostate cancer. Exp Biol Med (Maywood) 233:1608-1614.
79. Park K, Woo M, Nam J, Kim JC (2006). Start codon polymorphisms in the Vitamin D receptor and colorectal cancer risk. Cancer Lett 237:199-206.
80. Pena-Chilet M, Ibarrola-Villava M, Martin-Gonzalez M, Feito M, Gomez-Fernandez C, Planelles D, et al. (2013). rs12512631 on the group specific complement (Vitamin D-binding protein GC) implicated in melanoma susceptibility. PLoS One 8:e59607.
81. Penna-Martinez M, Ramos-Lopez E, Stern J, Hinsch N, Hansmann ML, Selkinski I, et al. (2009). Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. Thyroid 19:623-628.
82. Purdue MP, Hartge P, Davis S, Cerhan JR, Colt JS, Cozen W, et al. (2007). Sun exposure, Vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma. Cancer Causes Control 18:989-999.
83. Raimondi S, Pasquali E, Gnagnarella P, Serrano D, Disalvatore D, Johansson HA, Gandini S (2014). BsmI polymorphism of Vitamin D receptor gene and cancer risk: a comprehensive meta-analysis. Mutat Res 769:17-34.
84. Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, et al. (2009). Vitamin D receptor gene polymorphisms, serum 25-hydroxyVitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 45:3271-3281.
85. Rowland GW, Schwartz GG, John EM, Ingles SA (2012). Calcium intake and prostate cancer among African Americans: effect modification by Vitamin D receptor calcium absorption genotype. J Bone Miner Res 27:187-194.
86. Ruza E, Sotillo E, Sierrasesumaga L, Azcona C, Patino-Garcia A (2003). Analysis of polymorphisms of the Vitamin D receptor, estrogen receptor, and collagen I alpha1 genes and their relationship with height in children with bone cancer. J Pediatr Hematol Oncol 25:780-786.
87. Shafia S, Qasim I, Aziz SA, Bhat IA, Nisar S, Shah ZA (2013). Role of Vitamin D receptor (VDR) polymorphisms in susceptibility to multiple myeloma in ethnic Kashmiri population. Blood Cells Mol Dis 51:56-60.
88. Sillanpaa P, Hirvonen A, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, et al. (2004). Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk. Pharmacogenetics 14:239-245.
89. Slattery ML, Wolff RK, Curtin K, Fitzpatrick F, Herrick J, Potter JD, et al. (2009). Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. Mutat Res 660:12-21.
90. Smedby KE, Eloranta S, Duvefelt K, Melbye M, Humphreys K, Hjalgrim H, et al. (2011). Vitamin D receptor genotypes, ultraviolet radiation exposure, and risk of non-Hodgkin lymphoma. Am J Epidemiol 173:48-54.
91. Song GG, Lee YH (2013). Vitamin D receptor FokI, BsmI, ApaI, and TaqI polymorphisms and susceptibility to ovarian cancer: a meta-analysis. Immunol Invest 42:661-672.
92. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008-2012.
93. Strugnell SA, DeLuca HF (1997). The Vitamin D receptor -structure and transcriptional activation. Proc Soc Exp Biol Med 215:223-228.
94. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, et al. (2008). Multiple genetic loci for bone mineral density and fractures. N Engl J Med 358:2355-2365.
95. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Koike H, et al. (2003). Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urol 10:261-266.
96. Swami S, Krishnan AV, Feldman D (2000). 1alpha, 25-DihydroxyVitamin D3 downregulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 6:3371-3379.
97. Szkandera J, Absenger G, Pichler M, Stotz M, Langsenlehner T, Samonigg H, et al. (2013). Association of common gene variants in Vitamin D modulating genes and colon cancer recurrence. J Cancer Res Clin Oncol 139:1457-1464.
98. Theodoratou E, Farrington SM, Tenesa A, McNeill G, Cetnarskyj R, Barnetson RA, et al. (2008). Modification of the inverse association between dietary Vitamin D intake and colorectal cancer risk by a FokI variant supports a chemoprotective action of Vitamin D intake mediated through VDR binding. Int J Cancer 123:2170-2179.
99. Thill M, Fischer D, Kelling K, Hoellen F, Dittmer C, Hornemann A, et al. (2010). Expression of Vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients. J Steroid Biochem Mol Biol 121:387-390.
100. Toptas B, Kafadar AM, Cacina C, Turan S, Yurdum LM, Yigitbasi N, et al. (2013). The Vitamin D receptor (VDR) gene polymorphisms in Turkish brain cancer patients. Biomed Res Int 2013:295791.
101. Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, et al. (2008). VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res14:3223-3229.
102. Touvier M, Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, et al. (2011). Metaanalysesof Vitamin D intake, 25-hydroxyVitamin D status, Vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol BiomarkersPrev 20:1003-1016.
103. Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, Cramer D, et al.(2009). Polymorphisms in the Vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res 69:1885-1891.
104. Uitterlinden AG, Fang Y, van Meurs JB, Pols HA, van Leeuwen JP (2004). Genetics and biology of Vitamin D receptor polymorphisms. Gene 338:143-156.
105. Van Houwelingen HC, Arends LR, Stijnen T (2002). Advanced methods in metaanalysis: multivariate approach and meta-regression. Stat Med 21:589-624.
106. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2008). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344-349.
107. Wang J, He Q, Shao YG, Ji M, Bao W (2013). Associations between Vitamin D receptor polymorphisms and breast cancer risk. Tumour Biol 34:3823-3830.
108. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. (2010). Common genetic determinants of Vitamin D insufficiency: a genomewide association study. Lancet 376:180-188.
109. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, et al. (2001).Functionally relevant polymorphisms in the human nuclear Vitamin D receptor gene. Mol Cell Endocrinol 177:145-159.
110. Xu Y, He B, Pan Y, Deng Q, Sun H, Li R, et al. (2014). Systematic review and meta-analysis on Vitamin D receptor polymorphisms and cancer risk. Tumour Biol 35:4153-4169.
111. Yao S, Zirpoli G, Bovbjerg DH, Jandorf L, Hong CC, Zhao H, et al. (2012). Variants in the Vitamin D pathway, serum levels of Vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. Breast Cancer Res 14:R58.
112. Yaylim-Eraltan I, Arzu Ergen H, Arikan S, Okay E, Ozturk O, Bayrak S, et al. (2007). Investigation of the VDR gene polymorphisms association with susceptibility to colorectal cancer. Cell Biochem Funct 25:731-737.
113. Zeljic K, Supic G, Stamenkovic Radak M, Jovic N, Kozomara R, Magic Z (2012). Vitamin D receptor, CYP27B1 and CYP24A1 genes polymorphisms association with oral cancer risk and survival. J Oral Pathol Med 41:779-787.
114. Zhou ZC, Wang J, Cai ZH, Zhang QH, Cai ZX, Wu JH (2013). Association between Vitamin D receptor gene Cdx2 polymorphism and breast cancer susceptibility. Tumour Biol 34:3437-3441.